Blinding assessment in clinical trials: A review of statistical methods and a proposal of blinding assessment protocol

Clinical Research and Regulatory Affairs

Volumn 27, Issue 2, 2010, Pages 42-51

  Bang, Heejung ^a   Flaherty, Stephen P ^b   Kolahi, Jafar ^c   Park, Jongbae ^b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Blinding assessment; Blinding index; Blinding protocol; Blinding questionnaire; Masking

Indexed keywords

ACETYLSALICYLIC ACID; WARFARIN;

ACUPUNCTURE; CEREBROVASCULAR ACCIDENT; CHI SQUARE TEST; CLINICAL RESEARCH; CLINICAL TRIAL; HEART ATRIUM FIBRILLATION; HUMAN; KAPPA STATISTICS; MCNEMAR TEST; METHODOLOGY; QUANTITATIVE ANALYSIS; QUESTIONNAIRE; RANDOMIZATION; REVIEW; SHAM PROCEDURE; STATISTICAL ANALYSIS;

EID: 77952569050     PISSN: 10601333     EISSN: 15322521     Source Type: Journal    
DOI: 10.3109/10601331003777444     Document Type: Review

References (43)

1. Henkin RI, Schecter PJ, Friedewald WT, Demets DL, Raff M. A double blind study of the effects of zinc sulfate on taste and smell dysfunction. American Journal of the Med Sciences 1976;272:285-299.
2. Furberg CD, Soliman EZ. Double-blindness protects scientific validity. J Thromb Haemostasis 2008;6:230-231.
3. Bausell RB, Lao L, Bergman S, Lee WL, Berman BM. Is acupuncture analgesia an expectancy effect? Preliminary evidence based on participants' perceived assignments in two placebo-controlled trials. Evaluation & the Health Professions 2005;28:9-26.
4. Shapiro S. Risks of estrogen plus progestin therapy: a sensitivity analysis of findings in the Women's Health Initiative randomized controlled trial. Climacteric 2003;6: 302-310.
5. Shapiro S. Looking to the 21st century: have we learned from our mistakes, or are we doomed to compound them? Pharmacoepidemiol Drug Safety 2004;13:257-265.
6. Garbe E, Suissa S.Issues to debate on the Women's Health Initiative (WHI) study. Hormone replacement therapy and acute coronary outcomes: methodological issues between randomized and observationals studies. Human Reprod 2004;19:8-13.
7. Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, Pitkin R, Rennie D, Schulz K, David S, Stroup DF. Improving the quality of reporting of randomized controlled trials. The CONSORT statement. Journal of the American Medical Association 1996;276:637-639. (Pubitemid 26278070)
8. Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel group randomized trials. JAMA 2001;285:1987-1991. (Pubitemid 32366951)
9. International Committee of Medical Journal Editors. Uniform requirements for manuscripts submitted to biomedical journals. Med Educ 1999;33:66-78.
10. Boutron I, Estellat C, Ravaud P. A review of blinding in randomized controlled trials found results inconsistent and questionable. J Clin Epidemiol 2005;58:1220-1226.
11. Fergusson D, Glass KC, Waring D, Shapiro S. Turning a blind eye: The success of blinding reported in a random sample of randomised, placebo controlled trials. British Medical Journal 2004;328:432.
12. Hrobjartsson A, Forfang E, Haahr MT, Als-Nielsen B, Brorson S. Blinded trials taken to the test: An analysis of randomized clinical trials that report tests for the success of blinding. International Journal of Epidemiology 2007;36:654-663
13. Kolohi J, Bang H, Park J. Towards a proposal for assessment of blinding success in clinical trials: up-to-date review. Community Dental Oral Epidemiol 2009;37:477-484.
14. Walter SD, Awasthi S, Jeyaseelan L. Pre-trial evaluation of the potential for unblinding in drug trials: a prototype example. Contemp Clin Trials 2005;26:459-468.
15. Bowling A. Mode of questionnaire administration can have serious effects on data quality. J Public Health 2007;27:281-291.
16. Hughes JR, Krahn D. Blindness and the validity of the doubleblind procedure. J Clin Psychopharmacol 1985;5:138-142.
17. Margraf J, Ehlers A, Roth WT. How 'blind' are double-blind studies? J Consult Clin Psychol 1991;59:184-187.
18. Kolahi J, Soolari A, Ghalayani P, Varshosaz J, Fazilaty M. Newly formulated chlorhexidine gluconate chewing gum that gives both anti-plaque effectiveness and an acceptable taste: A double blind, randomized, placebo-controlled trial. Int Acad Periodontol 2008;10:38-44.
19. Wisner KL, Perel JM, Peindl KS, Hanusa BH, Findling RL, Rapport D. Prevention of recurrent postpartum depression: a randomised clinical trial. Journal of Clinical Psychiatry 2001;62:82-86.
20. James KE, Bloch DA, K.K. L, Kraemer HC, Fuller RK. An index for assessing blindness in a multi-centre clinical trial: Disulfiram for alcohol cessation - a VA cooperative study. Statistics in Medicine 1996;15:1421-1434.
21. Bang H, Ni L, Davis CE. Assessment of blinding in clinical trials. Contr Clin Trials 2004;25:143-156.
22. Park J, White AR, James MA, Hemsley AG, Johnson P, Chambers J. Acupuncture for subacute stroke rehabilitation: A sham-controlled, subject- and assessor-blind, randomized trial. Archives of Internal Medicine 2005;165:2026-2031.
23. Rimm AA, Bortin M. Clinical trials as a religion. Biomedicine 1978;28:60-63.
24. Bang H, Ni L, Davis CE. Response to Henneicke-von- Zepelin and Hemilä's comment. Contr Clin Trials 2005;26: 514-515.
25. Hertzberg V, Chimowitz M, Lynn M, Chester C, Asbury W, Cotsonis G. Use of dose modification schedules is effective for blinding trials of warfarin: Evidence from the WASID study. Clinical Trials 2008;5:23-30.
26. Chimowitz MI, Lynn MJ, Howlett-Smith H, Stern BJ, Hertzberg VS, Frankel MR, Levine SR, Chaturvedi S, Kasner SE, Benesch CG, Sila CA, Jovin TG, Romano JG. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. New England Journal of Medicine 2005;352:1305-1316.
27. Ezekowitz MD, Bridgers SL, James KE, Carliner CL, Gornick CC, Krause-Steinrauf H, Kurtzke JF, Nazarian SM, Radford MJ. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. New England Journal of Medicine 1992;327:1406-1412.
28. Hansson L, Hedner T, Dahlöf B.Prospective randomized open blinded end-point (PROBE) study. A novel design for intervention trials. Blood Pressure 1992;1:113-119.
29. Smith DH, Neutel JM, Lacourcière Y, Kempthorne-Rawson J. Prospective, randomized, open-label, blinded-endpoint (PROBE) designed trials yield the same results as doubleblind, placebo-controlled trials with respect to ABPM measurements. Journal of Hypertension 2003;21:1291-1298.
30. Büller HR, Halperin JL, Bounameaux H, Prins M. Doubleblind studies are not always optimum for evaluation of a novel therapy: the case of new anticoagulants. Journal of Thrombosis and Haemostasis 2008;6:227-229.
31. Casteels M, Flamion B. Open-label trials and drug registration: a European regulator's view. J Thromb Haemostasis 2008;6:232-234.
32. Park J, Bang H, Canette I. Blinding in controlled trials, time to do it better. Complement Ther Med 2008;16:121-123.
33. Sackett DL. Turning a blind eye: why we don't test for blindness at the end of our trials. BMJ 2004;328: 1136.
34. Henneicke-von Zepelin HH. Letter to the editor. Contemp Clin Trials 2005;26:512.
35. Hemilä H. Assessment of blinding may be inappropriate after the trial. Contemp Clin Trials 2005;26:512-514.
36. Lao L, Bergman S, Hamilton GR, Langenburg P, Berman B, Evaluation of acupuncture for pain control after oral surgery: A placebo-controlled trial. Archives of Otolaryngology Head and Neck Surgery 1999;125:567-572.
37. Smith MJ, Tong HC. Manual acupuncture for analgesia during electromyography: a pilot study. Arch Phys Med Rehab 2005;86:1741-1744.
38. Schulz K. Assessing allocation concealment and blinding in randomised controlled trials: why bother? Evidence-Based Med 2000;5:36-37.
39. Boutron I, Guittet L, Estellat C, Moher D, Hrobjartsson A, Ravaud P. Reporting methods of blinding in randomized trials assessing nonpharmacological treatments. PLoS Med 2007;4:e61.
40. Boutron I, Moher D, Altman D, Schulz K, Ravaud P. Extending the CONSORT statement to randomized trials of nonpharmacologic treatment: explanation and elaboration. Annals of Internal Medicine 2008;148:295-309. (Pubitemid 351665487)
41. Balk E, Bonis PAL, Moskowitz H, Schmid C, Ioannidis JPA, Wang C, Lau J. Correlation of quality measures with estimates of treatment effect in meta-analyses of randomized controlled trials. JAMA 2002;287:2973-2982.
42. Wood L, Egger M, Gluud L, Schulz K, Jni P, Altman D, Gluud C, Martin R, Wood AJG, Sterne JAC. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ. British medical journal (Clinical research ed.) 2008;336:601-605.
43. Haynes RB. Incorporating allocation concealment and blinding in randomised controlled trials. Evidence-Based Med 2000;5:38.